Neuroendocrine tumors (NETs) of the skin or soft tissue are rare (mostly described as sites
of metastasis), whereas primary soft-tissue NETs are extremely rare; they are usually …

The present study aimed at exploring the patient and imaging characteristics of primary
neuroendocrine tumors (NETs) of rare sites who presented with metastatic and/or advanced …

Neuroendocrine tumor (NET) occurring in association with other endocrine syndromes forms
a distinct entity. The aim was to assess the therapy response profile of the routine peptide …

Peptide receptor radionuclide therapy (PRRT) is an established treatment in advanced
neuroendocrine tumors (NETs), which overexpressed somatostatin receptors. However …

BACKGROUND: Treatment with 90Y-or 177Lu-DOTATOC has recently been introduced in
the palliative treatment of somatostatin receptor–expressing neuroendocrine tumors (NETs) …

Background This study was conducted to evaluate the clinical efficacy and safety of peptide
receptor radionuclide therapy (PRRT) using 177 Lu-DOTA0-Tyr3-octreotate (DOTATATE) in …

Introduction The peptide receptor radionuclide therapy (PRRT) with 90 Y and 177 Lu is a
form of molecular targeted therapy for inoperable or disseminated neuroendocrine tumors …

Neuroendocrine tumor (NET) is a rare tumor that has been observed in different sites such
as lungs and throughout the gastrointestinal tract. Clinical features are usually non-specific …

Abstract Purpose 177Lu-Dotatate is an emerging treatment modality for patients with
unresectable or metastatic well-differentiated NETs. This study examines survival predictors …

Neuroendocrine tumors (NETs) originate from single or clustered neuroendocrine cells,
distributed in the gastrointestinal tract, urogenital tract, endocrine, and bronchopulmonary …